MUC1 Peptide Pool, human

The MUC1 950–958 peptide (sequence: STAPPVHNV) is a defined HLA-A*02:01-restricted epitope derived from human Mucin-1 (MUC1; UniProt P15941). It is synthesized in its naturally presented MHC class I format and is optimized for the stimulation and analysis of antigen-specific CD8⁺ T cells. This single epitope peptide (IEDB ID 459700) enables precise functional interrogation of MUC1-specific cytotoxic T-cell responses in immunological and oncological research. Scientific Background MUC1 is a transmembrane mucin expressed on epithelial cells and widely recognized as a tumor-associated antigen. In malignant transformation, MUC1 becomes: Highly overexpressed Aberrantly glycosylated Mislocalized within the cell These alterations contribute to tumor progression, immune modulation, and altered signaling pathways. Because of these tumor-specific changes, MUC1-derived epitopes are frequently recognized by the immune system and have been validated in numerous CD8⁺ T-cell studies. The HLA-A*02:01-restricted epitope STAPPVHNV represents a well-characterized target for antigen-specific T-cell activation and immune monitoring. Applications The MUC1 950–958 peptide is suitable for: IFN-γ ELISpot assays Intracellular cytokine staining (ICS) Cytotoxicity assays T-cell proliferation assays Antigen-specific T-cell expansion Dendritic cell pulsing Immune monitoring in cancer research Its defined sequence allows focused analysis of epitope-specific CD8⁺ T-cell responses, making it particularly useful for mechanistic studies and translational oncology research. Positioning Within the MUC1 Research Portfolio While overlapping peptide pools enable full-length antigen screening and epitope discovery, single defined peptides such as MUC1 950–958 allow high-specificity functional validation and quantitative immune monitoring in HLA-typed cohorts. This peptide is therefore ideally suited for: Targeted immune response analysis Validation of vaccine-induced T-cell responses Monitoring of MUC1-directed immunotherapies

The peptide VPGWGIALL is a defined epitope derived from the human Mucin-1 (MUC1) protein and presented by the MHC class I allele HLA-B*07:02. This synthetic peptide is designed for the stimulation and analysis of MUC1-specific CD8⁺ T-cell responses in immunological assays. MUC1 is a transmembrane mucin that is normally expressed on epithelial cells, where it contributes to the protective mucosal barrier. In many malignancies—including breast, ovarian, pancreatic, and bladder cancer—MUC1 is strongly overexpressed and aberrantly glycosylated, which can expose peptide epitopes to the immune system and make the protein an important tumor-associated antigen. As a result, MUC1-derived peptides are widely used in cancer immunology research and in studies investigating antigen-specific T-cell responses. The MUC1 VPGWGIALL peptide (HLA-B*07:02) is synthesized to match the naturally presented epitope and can be used to stimulate antigen-specific T cells in a variety of experimental settings. Typical applications include ELISpot assays, intracellular cytokine staining (ICS), cytotoxicity assays, and T-cell proliferation assays, enabling researchers to monitor and characterize MUC1-directed immune responses. This peptide provides a reliable tool for cancer immunology, antigen-specific T-cell analysis, and immune monitoring studies involving MUC1-associated tumor antigens.